title: Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.
authors.affiliation: a Department of Medical Oncology , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
authors.forename: J J M
authors.initials: JJM
authors.lastname: Kwakman
authors.affiliation: b Department of Medical Oncology , Hospital Gelderse Vallei , Ede , The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Baars
authors.affiliation: c Department of Gastroenterology and Hepatology , The Netherlands Cancer Institute , Amsterdam , The Netherlands.
authors.forename: H
authors.initials: H
authors.lastname: Boot
authors.affiliation: d Department of Medical Oncology , Jeroen Bosch Hospital , Den Bosch , The Netherlands.
authors.forename: J F M
authors.initials: JFM
authors.lastname: Pruijt
authors.affiliation: e Department of Medical Oncology , Odense University Hospital , Odense , Denmark.
authors.forename: S B
authors.initials: SB
authors.lastname: Winther
authors.affiliation: e Department of Medical Oncology , Odense University Hospital , Odense , Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Pfeiffer
authors.affiliation: a Department of Medical Oncology , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands.
authors.forename: C J A
authors.initials: CJA
authors.lastname: Punt
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000069287:Capecitabine / Q000009:adverse effects*; D003718:Denmark / Q000453:epidemiology; D004338:Drug Combinations; D057915:Drug Substitution / Q000009:adverse effects / Q000379:methods; D005260:Female; D060831:Hand-Foot Syndrome / Q000175:diagnosis / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D009426:Netherlands / Q000453:epidemiology; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects*; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects*; D016896:Treatment Outcome; D019366:Western World
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000069287:Capecitabine